Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Data show that HIV-infected older people not taking HAART have double the risk of death

HIV is often regarded as a disease of young people, due to its status as a drug-related or sexually transmitted disease. However, the number of people over age 50 who are infected with HIV is significant--and growing--according to an article in the Sept. 15 issue of Clinical Infectious Diseases, now available online.

30 Aug 2005

Lorus identifies novel class of lead drug candidates from small molecule anticancer program

Lorus Therapeutics has announced the continued success in the development of its small molecule anticancer program with the selection of a sub-class of lead molecules from the Company's small molecule program.

24 Aug 2005

Firefly protein lets researchers monitor molecule known as IKK (for IKappa kinase) linked to cancer

Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.

9 Aug 2005

Genelabs drug discovery team advances compounds against the hepatitis C virus

Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.

4 Aug 2005

Analysis of the Phase I/II clinical trial of HIV drug candidate PA-457

V.I. Technologies (Vitex) and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil.

26 Jul 2005

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Human Genome Sciences has announced that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin

19 Jul 2005

Fine tuning drug levels in neuroblastoma patients is effective

Monitoring and fine tuning the levels of the cancer drug topotecan in children with neuroblastoma holds promise for maximizing the drug's effectiveness while reducing its toxicity, according to investigators at St. Jude Children's Research Hospital.

19 Jun 2005

Fine tuning drug levels in neuroblastoma patients is effective

16 Jun 2005

Non-profit public-private partnership develops affordable, new drug regimens for tuberculosis

The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.

14 Jun 2005

Novel topical treatment of psoriasis

Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis.

2 Jun 2005

Statins appear to be safe for people with fatty liver disease

Statins appear to be safe for people with fatty liver disease who could benefit from their cholesterol-lowering capabilities, concludes a review paper published in the April 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

28 Mar 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

Renovis announces investigational medicine for multiple sclerosis study

Renovis announced today the initiation of a Phase Ia clinical trial for REN-850, an investigational oral small molecule that is being targeted for the treatment of multiple sclerosis (MS).

14 Feb 2005

Ximelagatran effective for preventing blood clots and stroke

A medication that could simplify anticoagulation therapy, ximelagatran, was found to be as effective as other common therapies for preventing stroke and recurrent blood clots

9 Feb 2005

New way to assess the potentially damaging effects of prenatal drug exposure

Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure--a technique that could also be used to monitor a fetus's response to therapeutic drugs--using sophisticated, noninvasive medical imaging tools.

7 Feb 2005

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004